Marilena Vrana Joins ARMONIA 2025 in Athens to Discuss Plasma Access
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”Why does the dependency of Europe on the US for plasma for fractionation persist? What does it mean for patient access and health-systems resilience?
These are some of the questions we will explore at ARMONIA’s 1st Conference on Primary Immunodeficiencies on 12 November in Athens, where I will represent PPTA Europe, Plasma Protein Therapeutics Association (PPTA).
Plasma and plasma-derived therapies availability is a public-health issue with very real consequences for people whose lives depend on them. I look forward to a forward-looking, evidence-based discussion with all stakeholders present.
CU in Athens.
12 November 2025
Wyndham Grand Athens
Agenda here.”
Keep up with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation